Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial

RCT (n=2,014) found the addition of trastuzumab to radiotherapy did not reduce the risk of ipsilateral breast cancer recurrence (HR, 0.81; 95% CI, 0.56 to 1.17).

Journal of Clinical Oncology